{"gene":"RB1","run_date":"2026-06-10T06:43:36","timeline":{"discoveries":[{"year":2001,"finding":"RB associates with the histone methyltransferase SUV39H1 and the methyl-lysine binding protein HP1 via its pocket domain in vivo. RB directs methylation of histone H3 (Lys9) and recruits HP1 to the cyclin E promoter, repressing cyclin E and cyclin A2 gene expression through chromatin-level silencing.","method":"Co-immunoprecipitation, chromatin immunoprecipitation (ChIP), transient transfection reporter assays, SUV39H1-disrupted fibroblasts","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, ChIP with endogenous proteins, functional genetic (knockout fibroblasts), and reporter assays; multiple orthogonal methods in one rigorous study","pmids":["11484059"],"is_preprint":false},{"year":1997,"finding":"RB physically interacts with hBRM (a SWI/SNF ATPase subunit) and can simultaneously bind both E2F1 and hBRM, targeting hBRM to E2F1. RB and hBRM cooperate to repress E2F1 transcriptional activity, and this cooperation requires the RB-binding domain and NTP-binding site of hBRM but not its bromodomain.","method":"Co-immunoprecipitation in vivo, transient transfection reporter assays, domain-deletion and mutation analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, functional reporter assays, structure-function mutagenesis of hBRM, single lab with multiple orthogonal methods","pmids":["9326598"],"is_preprint":false},{"year":2012,"finding":"SMYD2 methylates RB1 protein at lysine 810 in vitro and in vivo. This lysine 810 methylation enhances subsequent phosphorylation of RB1 at Ser807/811, accelerates E2F transcriptional activity, and promotes cell cycle progression through G1/S.","method":"In vitro methyltransferase assay, LC-MS/MS identification of methylation site, immunoprecipitation, cell cycle analysis, SMYD2 knockdown","journal":"Neoplasia (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic assay with mass spectrometry site identification, validated in vivo by Co-IP and cell cycle readout; multiple orthogonal methods in single study","pmids":["22787429"],"is_preprint":false},{"year":2001,"finding":"RB colocalizes with Polycomb group (PcG) protein complexes in the nucleus and forms a repressor complex with PcG proteins that blocks entry into mitosis. RB is required for the association of PcG complexes with their nuclear targets.","method":"Co-immunoprecipitation, immunofluorescence colocalization, cell cycle analysis","journal":"Molecular cell","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP and localization with functional cell cycle readout, but single lab and limited mechanistic depth in the abstract","pmids":["11583618"],"is_preprint":false},{"year":2016,"finding":"pRB uses a cell-cycle-independent interaction with E2F1 to recruit EZH2 to diverse repetitive genomic sequences (simple repeats, satellites, LINEs, endogenous retroviruses). An F832A point mutation in Rb1 abolishes this recruitment; loss of pRB-EZH2 complexes disperses H3K27me3 from these repeat loci and permits their expression.","method":"Co-immunoprecipitation, ChIP-seq, knock-in mouse model (F832A mutation), gene expression analysis","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — structure-function mutation in vivo, ChIP-seq, reciprocal Co-IP, mutant mouse strain with defined phenotype; multiple orthogonal methods","pmids":["27889452"],"is_preprint":false},{"year":2024,"finding":"CDK2- or CDK4/6-mediated phosphorylation of RB1 at the conserved T373 residue creates a primed, intermediate state of partial E2F activation. T373-phosphorylated RB remains bound to chromatin but dissociates fully only upon hyperphosphorylation at many sites. T373 is preferentially phosphorylated initially due to its slower dephosphorylation rate. This intermediate state allows cells to remain reversibly uncommitted before triggering the positive CDK2-E2F feedback loop.","method":"Single-cell live imaging of E2F and CDK2 reporters, phospho-specific immunofluorescence, pharmacological CDK inhibition, site-specific RB phosphorylation analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — single-cell live reporters, phospho-site-specific biochemistry, multiple pharmacological perturbations; rigorous mechanistic dissection with multiple orthogonal approaches","pmids":["38926571"],"is_preprint":false},{"year":2006,"finding":"The arginine methyltransferase PRMT2 binds RB through its AdoMet binding domain (unlike PRMT1, PRMT3, PRMT4 which do not bind RB). PRMT2 represses E2F1 transcriptional activity in an RB-dependent manner by forming a ternary complex with E2F1 in the presence of RB. PRMT2-null MEFs show increased E2F activity and accelerated S-phase entry.","method":"Co-immunoprecipitation, reporter assays, PRMT2 gene targeting in mice, cell cycle analysis","journal":"Experimental cell research","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, reporter assays, PRMT2 knockout mice with defined cellular phenotype; multiple orthogonal methods and genetic validation","pmids":["16616919"],"is_preprint":false},{"year":2010,"finding":"RB physically associates with and stabilizes the pancreatic transcription factor Pdx-1 via a conserved RB-interaction motif (RIM) in Pdx-1 that is also present in E2Fs. Point mutations within the RIM reduce RB-Pdx-1 complex formation, destabilize Pdx-1, and promote its proteasomal degradation. Glucose regulates RB/Pdx-1 complex formation and Pdx-1 stability. RB occupies promoters of β-cell-specific genes; RB knockdown reduces Pdx-1 and its target gene expression.","method":"Co-immunoprecipitation, site-directed mutagenesis (RIM mutations), ChIP, siRNA knockdown, proteasome inhibitor experiments, RB-deficient mouse phenotype","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, structure-function mutagenesis, ChIP, in vivo mouse model; multiple orthogonal methods establishing a novel RB substrate interaction mechanism","pmids":["21399612"],"is_preprint":false},{"year":2016,"finding":"Dephosphorylated RB associates with ZEB1 (a transcriptional regulator of EMT markers E- and N-cadherin) and inhibits ZEB1 transcriptional activity. PP1-mediated dephosphorylation of RB (via PNUTS knockdown) reduces EMT in invasive cancer cells in 3D culture in an RB-dependent manner.","method":"shRNA silencing of PNUTS, Co-immunoprecipitation, 3D Matrigel culture, reporter assays, Western blot","journal":"Cancer biology & therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP, functional cellular assay, and RB-null controls confirm RB dependence; single lab, single paper","pmids":["27645778"],"is_preprint":false},{"year":2016,"finding":"SUMO1 conjugation of RB and Lamin A/C, modulated by the SUMO protease SENP1, is required for the RB-Lamin A/C interaction. This SUMO1-dependent complex protects both RB and Lamin A/C from proteasomal degradation.","method":"Sumoylation assays, Co-immunoprecipitation, SENP1 overexpression/knockdown, proteasome inhibitor experiments","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP, biochemical sumoylation assay, functional proteasomal degradation readout; single lab, single paper","pmids":["27270425"],"is_preprint":false},{"year":2010,"finding":"RB triggers autophagy through repression of E2F1 activity. RB activators p16INK4a and p27/Kip1 induce autophagy in an RB-dependent manner. E2F1 antagonizes RB-induced autophagy, and downregulation of E2F1 leads to high autophagy levels.","method":"Autophagy assays, RB/E2F1 overexpression and knockdown, epistasis by double knockdown","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — genetic epistasis (RB-dependent rescue), functional autophagy readout; single lab, single paper","pmids":["20807803"],"is_preprint":false},{"year":2015,"finding":"Ras induces formation of a complex between NORE1A and the phosphatase PP1A, which promotes dephosphorylation and activation of RB. Suppression of RB reduces NORE1A-induced senescence, placing RB downstream of Ras/NORE1A/PP1A in oncogene-induced senescence.","method":"Co-immunoprecipitation, RB knockdown, senescence assays, PP1A-NORE1A interaction pulldown","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP, epistasis via RB suppression, functional senescence readout; single lab, single paper","pmids":["26677227"],"is_preprint":false},{"year":2018,"finding":"Aspartate beta-hydroxylase (ASPH) promotes direct protein interaction between RB1, cyclin-dependent kinases, and cyclins, thereby promoting RB1 phosphorylation. ASPH knockdown reduces RB1 phosphorylation and inhibits cholangiocarcinoma growth in vitro and in vivo.","method":"Co-immunoprecipitation, ASPH knockdown, phospho-RB1 immunoassay, xenograft mouse model, 2-OG dioxygenase inhibitor treatment","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP demonstrating RB1-CDK-cyclin complex modulated by ASPH, supported by in vivo xenograft; single lab, single paper","pmids":["29733964"],"is_preprint":false},{"year":2002,"finding":"Active (constitutively hypophosphorylated) RB inhibits cell cycle progression at the late G1/S boundary not by suppressing cyclin E expression or CDK2/cyclin E activity, but by causing coordinate transcriptional repression and accelerated degradation of cyclin A, attenuating CDK2/cyclin A-dependent events.","method":"Inducible constitutively active RB allele (PSM-RB), cell cycle synchronization, mRNA and protein analysis, CDK kinase assays, centrosome duplication assay","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — inducible gain-of-function allele, kinase assays, multiple mechanistic readouts; single lab, multiple orthogonal methods","pmids":["12027450"],"is_preprint":false},{"year":2006,"finding":"Rb1 protein (pRb) binds to Runx2 and potentiates its osteogenic differentiation activity. pRb acts with E2F to suppress PPARγ (master adipogenic activator). Rb status thus controls mesenchymal stem cell fate choice between osteoblast and adipocyte lineages in vivo.","method":"Mouse conditional knockout models, lineage tracing, in vivo bone and adipose tissue phenotyping, co-immunoprecipitation (referenced in abstract as prior in vitro work; in vivo epistasis confirmed here)","journal":"Nature","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo conditional knockout mouse models with defined lineage phenotypes; some mechanistic claims (Runx2 binding) based on referenced prior in vitro work, confirmed in vivo by genetic epistasis","pmids":["20686481"],"is_preprint":false},{"year":1998,"finding":"RB1 is cleaved by caspase-3-like activity at its carboxyl terminus during apoptosis. During apoptosis, hyperphosphorylated RB is first dephosphorylated to the hypophosphorylated form, which is then cleaved by caspase activity. The unphosphorylated (p110) form of RB is resistant to cleavage and functions as an inhibitor of apoptosis; a caspase-resistant RB1 attenuates the death response to TNF-α.","method":"In vitro caspase cleavage assays, cell death assays with TNF-α, immunoblotting of RB phospho-forms, caspase-resistant mutant expression","journal":"Trends in cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical caspase assays, functional caspase-resistant mutant; replicated across multiple studies cited in abstract","pmids":["9695821"],"is_preprint":false},{"year":2009,"finding":"RB1CC1 (FIP200) directly binds to a GC-rich region 201 bp upstream of the RB1 promoter and activates RB1 transcription. The C-terminus of RB1CC1 is required for its nuclear localization and subsequent RB1 promoter activation.","method":"Chromatin immunoprecipitation, luciferase reporter assays, electrophoretic mobility shift assay (EMSA), Western blot, immunohistochemistry","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, EMSA, and reporter assays establishing direct promoter binding; single lab with multiple orthogonal methods","pmids":["19437535"],"is_preprint":false},{"year":2010,"finding":"RB1CC1 (FIP200) forms a nuclear complex with hSNF5 and/or p53 that activates transcription of RB1, p16, and p21. RB1CC1 binds hSNF5 and p53 as identified by immunoprecipitation and immunofluorescence.","method":"Co-immunoprecipitation, chromatin immunoprecipitation, luciferase reporter assays, flow cytometry, immunofluorescence","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP identifying complex partners, ChIP, and reporter assays; single lab, single paper","pmids":["20614030"],"is_preprint":false},{"year":2010,"finding":"The RB/E2F pathway directly regulates neogenin expression: RB represses E2F-mediated transcription of neogenin (a receptor for netrin-1 involved in cell migration), and E2F3 occupies E2F consensus sites on the neogenin promoter in native chromatin. Loss of Rb results in increased neogenin expression, aberrant neuronal migration and adhesion in response to netrin-1.","method":"ChIP, promoter reporter assays, Rb conditional knockout mouse, ex vivo electroporation, migration assays","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP with E2F3 antibody on native chromatin, reporter assays, conditional KO mouse with functional neuronal migration phenotype; single lab, multiple orthogonal methods","pmids":["21059867"],"is_preprint":false},{"year":2011,"finding":"Loss of Rb1 in satellite cells (using conditional Pax7CreER;Rb1 deletion) causes re-entry of quiescent satellite cells into replication, resulting in 5-fold expansion of satellite cells and 3-fold increase in myoblasts, while diminishing terminal differentiation. This establishes pRb as a regulator of muscle satellite cell quiescence.","method":"Conditional mouse knockout (Pax7CreER;Rb1flox), satellite cell counting, BrdU incorporation, cardiotoxin injury/regeneration assay, pharmacological PP1 inhibition","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean conditional KO with specific cellular phenotypes; single lab, in vivo mouse model with multiple readouts","pmids":["21478154"],"is_preprint":false},{"year":2005,"finding":"Mitf cooperates physically with Rb1 to potentiate Mitf-mediated transcriptional activation. The interaction between Mitf and hypophosphorylated Rb1 enhances Mitf's ability to activate the p21Cip1 promoter, leading to G1 arrest. Mitf-induced cell cycle arrest depends on this p21Cip1 induction.","method":"Co-immunoprecipitation, luciferase reporter assays, cell cycle analysis, p21Cip1 promoter activation assays","journal":"Nature","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, promoter reporter with functional rescue, cell cycle readout; single lab with multiple orthogonal methods","pmids":["15716956"],"is_preprint":false},{"year":2006,"finding":"RB family members (p107 and p130) and E2F transcription factors bind directly to the RB1 promoter in vivo, modulating RB transcription as a regulatory feedback mechanism in specific cell populations.","method":"ChIP on RB1 promoter, transgenic eGFP-BAC reporter mice, genetic analyses with Rb, p107, and p130 mutant alleles","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP establishing direct promoter binding, validated in vivo with reporter transgenic and triple-mutant mice; single lab","pmids":["20100864"],"is_preprint":false},{"year":2016,"finding":"RB loss induces upregulation of the cell motility receptor RHAMM via the RB/E2F pathway, which stabilizes F-actin polymerization by controlling ROCK signaling, promoting epithelial-mesenchymal transition, motility, and invasion. Pharmacological or genetic inhibition of RHAMM blocks the metastatic phenotype caused by RB loss.","method":"Multiple murine cancer models with RB knockout, gene expression analysis, pharmacological RHAMM inhibition, RHAMM genetic modulation, invasion/motility assays, F-actin polymerization assays","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple in vivo mouse models, defined pathway (RB/E2F→RHAMM→ROCK→F-actin), pharmacological and genetic rescue; single lab","pmids":["27923835"],"is_preprint":false},{"year":2006,"finding":"An E2F-binding-deficient Rb1 point mutant (R654W, defective for binding E2F1, E2F2, E2F3) rescues erythrocyte and fetal liver macrophage differentiation defects in Rb1-null embryos, extending survival by at least 2 days beyond null lethality, but does not rescue retinal differentiation defects. This establishes that Rb1's role in certain differentiation events is genetically separable from E2F1/2/3 binding.","method":"Knock-in mouse model (R654W mutation), embryonic phenotype analysis, histology, cell cycle analysis, comparison with null embryos","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vivo knock-in mutagenesis with precise separation-of-function, multiple tissue phenotypes analyzed; rigorous genetic approach establishing mechanistic separation","pmids":["16449662"],"is_preprint":false},{"year":1999,"finding":"Rb and p27 cooperate to suppress tumor development through overlapping but distinct pathways: Rb+/-p27-/- double mutant mice develop more aggressive and earlier-onset pituitary and thyroid tumors than either single mutant, and pituitary tumor development in Rb+/- mice correlates with reduced p27 expression. This genetic epistasis places p27 and Rb on overlapping but not strictly linear tumor suppressor pathways.","method":"Mouse double-mutant genetic analysis (Rb+/- x p27-/-), tumor phenotype comparison, p27 mRNA and protein expression analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in vivo with defined tumor phenotypes and molecular marker analysis; single study, in vivo mouse models","pmids":["10339596"],"is_preprint":false}],"current_model":"RB1 (pRB) is a multifunctional tumor suppressor that primarily restrains cell cycle progression by binding E2F transcription factors through its pocket domain and actively repressing E2F target gene promoters via recruitment of chromatin-modifying co-repressors including HDACs, the SWI/SNF ATPase hBRM, the histone H3K9 methyltransferase SUV39H1 (which directs HP1 binding), and the H3K27 methyltransferase EZH2 (recruited in a cell-cycle-independent manner to silence repetitive sequences); pRB phosphorylation status—governed by cyclin-CDK complexes and reversed by PP1/NORE1A and related phosphatases—dictates its activity, with sequential phosphorylation first at T373 creating a primed intermediate state before full hyperphosphorylation releases E2F and triggers S-phase commitment; beyond E2F control, pRB stabilizes lineage-specific transcription factors (e.g., Pdx-1, Runx2), cooperates with Mitf to induce p21Cip1-dependent differentiation arrest, is methylated at K810 by SMYD2 to enhance CDK-mediated phosphorylation, is sumoylated in a SENP1-regulated manner enabling its protective interaction with Lamin A/C, and is cleaved by caspase-3 during apoptosis—collectively establishing pRB as an integrator of proliferation, differentiation, genome stability, and cell death signals."},"narrative":{"mechanistic_narrative":"RB1 (pRB) is a tumor suppressor that restrains cell cycle progression by binding E2F transcription factors and converting their target promoters into transcriptionally silent chromatin [PMID:11484059, PMID:9326598]. pRB does not act simply as a steric blockade: it recruits the H3K9 methyltransferase SUV39H1 and the methyl-lysine reader HP1 to genes such as cyclin E and cyclin A2, directing histone H3 Lys9 methylation and chromatin-level repression [PMID:11484059], and it physically engages the SWI/SNF ATPase hBRM to repress E2F1 activity through its RB-binding and NTP-binding modules [PMID:9326598]. Through a cell-cycle-independent interaction with E2F1, pRB also delivers EZH2 to repetitive genomic sequences (satellites, LINEs, endogenous retroviruses), maintaining H3K27me3 and silencing these loci—an activity abolished by the F832A pocket mutation [PMID:27889452]. pRB activity is set by its phosphorylation state: sequential CDK2/CDK4-6 phosphorylation begins at T373 to create a chromatin-bound, reversibly uncommitted intermediate before hyperphosphorylation fully releases E2F and commits cells to S phase [PMID:38926571], while active hypophosphorylated pRB enforces the late G1/S boundary largely by repressing and destabilizing cyclin A [PMID:12027450]. These phosphorylation events are tuned by additional modifications—SMYD2 methylation at K810 primes pRB for CDK phosphorylation [PMID:22787429]—and reversed by PP1-based phosphatase activities, including a NORE1A/PP1A complex that activates pRB during Ras-induced senescence [PMID:26677227]. Beyond E2F control, pRB acts as a stabilizing cofactor for lineage transcription factors, binding and protecting Pdx-1 in pancreatic β-cells [PMID:21399612], potentiating Runx2-driven osteogenesis while suppressing adipogenesis to govern mesenchymal fate [PMID:20686481], and cooperating with Mitf to induce p21Cip1-dependent G1 arrest [PMID:15716956]; a separation-of-function knock-in (R654W) demonstrates that some differentiation roles are genetically independent of E2F1/2/3 binding [PMID:16449662]. pRB additionally functions in autophagy [PMID:20807803], satellite-cell quiescence [PMID:21478154], suppression of EMT and metastasis through ZEB1 and the RHAMM/ROCK axis [PMID:27645778, PMID:27923835], and apoptosis, where caspase-3 cleaves its C-terminus and the uncleavable form acts as a death inhibitor [PMID:9695821]. RB1 transcription is itself feedback-regulated by E2F and RB-family proteins binding its promoter [PMID:20100864] and activated by an RB1CC1/FIP200-containing nuclear complex [PMID:19437535, PMID:20614030].","teleology":[{"year":1997,"claim":"Established that pRB represses E2F not merely by binding it but by physically recruiting a chromatin-remodeling ATPase, introducing the concept of pRB as a co-repressor scaffold.","evidence":"Co-IP and structure-function mutagenesis showing pRB simultaneously binds E2F1 and hBRM and cooperatively represses E2F1 transcription","pmids":["9326598"],"confidence":"High","gaps":["Did not resolve whether hBRM acts on nucleosome positioning at endogenous E2F promoters","No genome-wide map of pRB-hBRM co-occupancy"]},{"year":1998,"claim":"Defined pRB as a node in apoptotic signaling by showing caspase cleavage inactivates it, linking its degradation to death-signal execution.","evidence":"In vitro caspase cleavage assays, RB phospho-form immunoblotting, and a caspase-resistant mutant in TNF-α death assays","pmids":["9695821"],"confidence":"Medium","gaps":["Physiological caspase responsible in vivo not fully defined","Downstream consequences of the cleaved fragment unresolved"]},{"year":1999,"claim":"Placed pRB and p27 on overlapping but non-linear tumor-suppressor pathways, showing combinatorial control of endocrine tumorigenesis.","evidence":"Rb+/- x p27-/- double-mutant mouse genetics with tumor phenotype and p27 expression analysis","pmids":["10339596"],"confidence":"Medium","gaps":["Molecular basis of cooperativity not delineated","Tissue specificity of the genetic interaction unexplained"]},{"year":2001,"claim":"Revealed the chromatin-silencing mechanism of pRB repression—recruitment of SUV39H1/HP1 to deposit H3K9 methylation at cell-cycle promoters—and its link to Polycomb-mediated mitotic control.","evidence":"Reciprocal Co-IP, ChIP on the cyclin E promoter in SUV39H1-knockout fibroblasts; separate Co-IP/colocalization with PcG complexes and cell-cycle readouts","pmids":["11484059","11583618"],"confidence":"High","gaps":["Generality of HP1/SUV39H1 recruitment across the E2F target set not established","PcG-pRB complex composition only partially defined (Medium-confidence)"]},{"year":2002,"claim":"Clarified how active pRB enforces the late G1/S boundary, showing the block operates through cyclin A repression and degradation rather than cyclin E/CDK2 suppression.","evidence":"Inducible constitutively active PSM-RB allele with CDK kinase assays, mRNA/protein and centrosome duplication readouts","pmids":["12027450"],"confidence":"Medium","gaps":["Mechanism of accelerated cyclin A degradation not identified","Single inducible system"]},{"year":2006,"claim":"Expanded pRB's repressive repertoire and differentiation roles—identifying PRMT2 as an RB-dependent E2F1 co-repressor, Runx2/PPARγ control of mesenchymal fate, and an E2F-independent differentiation function via the R654W separation-of-function allele.","evidence":"PRMT2-null MEFs and ternary-complex Co-IP; conditional Rb knockout lineage tracing; R654W knock-in mouse rescue of erythroid/macrophage but not retinal defects","pmids":["16616919","20686481","16449662"],"confidence":"High","gaps":["Identity of the E2F-independent effectors in differentiation tissues unknown","Whether PRMT2 methylation activity is required for repression not resolved"]},{"year":2009,"claim":"Showed RB1 expression is transcriptionally controlled by FIP200/RB1CC1 binding its promoter, identifying an upstream regulator of pRB abundance.","evidence":"ChIP, EMSA, and luciferase reporter assays mapping RB1CC1 binding to a GC-rich element upstream of RB1","pmids":["19437535"],"confidence":"Medium","gaps":["Physiological signals controlling RB1CC1 nuclear activity unclear","Single-lab promoter study"]},{"year":2010,"claim":"Extended pRB function into autophagy, neuronal migration, and protein-stabilizing cofactor roles, and defined an RB1CC1/hSNF5/p53 transcriptional activation complex for RB1, p16 and p21.","evidence":"RB/E2F1 epistasis autophagy assays; ChIP/reporter and conditional KO for neogenin; Co-IP/RIM mutagenesis stabilizing Pdx-1; Co-IP/ChIP for the RB1CC1-hSNF5-p53 complex","pmids":["20807803","21059867","21399612","20614030"],"confidence":"Medium","gaps":["Autophagy effector genes downstream of E2F1 unidentified","Whether the RB1CC1-p53 complex operates in normal vs stressed cells unclear"]},{"year":2011,"claim":"Defined pRB as a guardian of stem-cell quiescence, showing its loss drives quiescent satellite cells back into cycle while impairing differentiation.","evidence":"Pax7CreER;Rb1flox conditional knockout with cell counting, BrdU, injury/regeneration, and PP1 inhibition","pmids":["21478154"],"confidence":"Medium","gaps":["Phosphatase regulating pRB in satellite cells not definitively identified","Single in vivo system"]},{"year":2012,"claim":"Identified a post-translational priming mechanism—SMYD2 methylation of pRB at K810 enhancing CDK phosphorylation—linking lysine methylation to cell-cycle release.","evidence":"In vitro methyltransferase assay with LC-MS/MS site mapping, Co-IP, and SMYD2-knockdown cell-cycle analysis","pmids":["22787429"],"confidence":"High","gaps":["Reader of K810 methylation not identified","Whether methylation directly alters CDK docking unresolved"]},{"year":2015,"claim":"Connected pRB activation to oncogene-induced senescence through a Ras/NORE1A/PP1A dephosphorylation circuit.","evidence":"Co-IP of NORE1A-PP1A, RB suppression epistasis, and senescence assays","pmids":["26677227"],"confidence":"Medium","gaps":["Direct PP1A dephosphorylation sites on pRB not mapped","Single-lab study"]},{"year":2016,"claim":"Defined a cell-cycle-independent pRB-EZH2 repeat-silencing activity and additional non-cell-cycle modifications and effectors (sumoylation/Lamin A/C protection, ZEB1/RHAMM-mediated suppression of EMT and metastasis).","evidence":"F832A knock-in mouse with ChIP-seq for EZH2/H3K27me3; SUMO/SENP1 assays for Lamin A/C; PNUTS knockdown 3D culture for ZEB1; multiple RB-knockout cancer models for RHAMM/ROCK","pmids":["27889452","27270425","27645778","27923835"],"confidence":"High","gaps":["How a single pocket residue (F832) discriminates repeat from gene targets unclear","Sumoylation and ZEB1 findings are Medium-confidence single-lab studies"]},{"year":2018,"claim":"Identified ASPH as a scaffolding factor promoting RB1-CDK-cyclin complex assembly and pRB phosphorylation in cancer.","evidence":"Co-IP, ASPH knockdown with phospho-RB1 readout, xenograft model, and dioxygenase inhibition","pmids":["29733964"],"confidence":"Medium","gaps":["Whether ASPH hydroxylase activity is required for complex assembly not resolved","Single-lab study"]},{"year":2024,"claim":"Resolved how pRB inactivation is graded over the cell cycle, showing T373 phosphorylation creates a chromatin-bound, reversibly uncommitted intermediate that precedes full hyperphosphorylation and S-phase commitment.","evidence":"Single-cell live imaging of E2F/CDK2 reporters, phospho-site-specific immunofluorescence, and pharmacological CDK inhibition","pmids":["38926571"],"confidence":"High","gaps":["Structural basis of partial vs full E2F release not defined","Phosphatase setting the slow T373 dephosphorylation rate not identified"]},{"year":null,"claim":"How the many pRB modifications (phosphorylation, K810 methylation, sumoylation, caspase cleavage) and its diverse partner set are integrated to select among proliferation, differentiation, senescence, autophagy, and apoptosis outcomes in a given cell remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking modification state to effector-complex choice","Tissue-specific partner usage incompletely mapped","Structural basis for pocket-domain discrimination among E2F, lineage factors, and co-repressors undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,4,13,20]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,4,6,7,20]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[1,4,6]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,7]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,3,4]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[0,4]},{"term_id":"GO:0005635","term_label":"nuclear envelope","supporting_discovery_ids":[9]}],"pathway":[{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[0,5,13]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,4,7,20]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[0,4]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[7,14,23]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[10]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[15]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[11]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[22,24]}],"complexes":["pRB-E2F1-EZH2 repeat-silencing complex","pRB-SUV39H1-HP1 repressor complex","pRB-E2F1-hBRM (SWI/SNF) repressor complex","pRB-PcG repressor complex"],"partners":["E2F1","SUV39H1","HP1","HBRM","EZH2","PRMT2","PDX-1","MITF"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P06400","full_name":"Retinoblastoma-associated protein","aliases":["p105-Rb","p110-RB1","pRb","Rb","pp110"],"length_aa":928,"mass_kda":106.2,"function":"Tumor suppressor that is a key regulator of the G1/S transition of the cell cycle (PubMed:10499802). The hypophosphorylated form binds transcription regulators of the E2F family, preventing transcription of E2F-responsive genes (PubMed:10499802). Both physically blocks E2Fs transactivating domain and recruits chromatin-modifying enzymes that actively repress transcription (PubMed:10499802). Cyclin and CDK-dependent phosphorylation of RB1 induces its dissociation from E2Fs, thereby activating transcription of E2F responsive genes and triggering entry into S phase (PubMed:10499802). RB1 also promotes the G0-G1 transition upon phosphorylation and activation by CDK3/cyclin-C (PubMed:15084261). Directly involved in heterochromatin formation by maintaining overall chromatin structure and, in particular, that of constitutive heterochromatin by stabilizing histone methylation. Recruits and targets histone methyltransferases SUV39H1, KMT5B and KMT5C, leading to epigenetic transcriptional repression. Controls histone H4 'Lys-20' trimethylation. Inhibits the intrinsic kinase activity of TAF1. Mediates transcriptional repression by SMARCA4/BRG1 by recruiting a histone deacetylase (HDAC) complex to the c-FOS promoter. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex (By similarity) (Microbial infection) In case of viral infections, interactions with SV40 large T antigen, HPV E7 protein or adenovirus E1A protein induce the disassembly of RB1-E2F1 complex thereby disrupting RB1's activity","subcellular_location":"Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P06400/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/RB1","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/RB1","total_profiled":1310},"omim":[{"mim_id":"621507","title":"MICROCEPHALY 31, PRIMARY, AUTOSOMAL RECESSIVE; MCPH31","url":"https://www.omim.org/entry/621507"},{"mim_id":"620974","title":"ZINC FINGER PROTEIN 862; ZNF862","url":"https://www.omim.org/entry/620974"},{"mim_id":"619722","title":"TRANSMEMBRANE PROTEIN 53; TMEM53","url":"https://www.omim.org/entry/619722"},{"mim_id":"618136","title":"MAD2L1-BINDING PROTEIN; MAD2L1BP","url":"https://www.omim.org/entry/618136"},{"mim_id":"618055","title":"CELLULAR REPRESSOR OF E1A-STIMULATED GENES 1; CREG1","url":"https://www.omim.org/entry/618055"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Primary cilium transition zone","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/RB1"},"hgnc":{"alias_symbol":["RB","PPP1R130"],"prev_symbol":["OSRC"]},"alphafold":{"accession":"P06400","domains":[{"cath_id":"1.10.472.170","chopping":"50-140","consensus_level":"high","plddt":87.1056,"start":50,"end":140},{"cath_id":"1.10.472.140","chopping":"161-176_184-246_264-342","consensus_level":"high","plddt":88.9366,"start":161,"end":342},{"cath_id":"1.10.472.10","chopping":"375-579_597-606","consensus_level":"high","plddt":92.2846,"start":375,"end":606},{"cath_id":"1.10.472.10","chopping":"652-771","consensus_level":"high","plddt":95.1501,"start":652,"end":771}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P06400","model_url":"https://alphafold.ebi.ac.uk/files/AF-P06400-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P06400-F1-predicted_aligned_error_v6.png","plddt_mean":76.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=RB1","jax_strain_url":"https://www.jax.org/strain/search?query=RB1"},"sequence":{"accession":"P06400","fasta_url":"https://rest.uniprot.org/uniprotkb/P06400.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P06400/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P06400"}},"corpus_meta":[{"pmid":"12204530","id":"PMC_12204530","title":"The RB and p53 pathways in cancer.","date":"2002","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/12204530","citation_count":1279,"is_preprint":false},{"pmid":"16936740","id":"PMC_16936740","title":"RB and cell cycle progression.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16936740","citation_count":932,"is_preprint":false},{"pmid":"11257102","id":"PMC_11257102","title":"The Rb/E2F pathway and cancer.","date":"2001","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11257102","citation_count":742,"is_preprint":false},{"pmid":"11484059","id":"PMC_11484059","title":"Rb targets histone H3 methylation and HP1 to promoters.","date":"2001","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/11484059","citation_count":720,"is_preprint":false},{"pmid":"23594950","id":"PMC_23594950","title":"Molecular mechanisms underlying RB protein function.","date":"2013","source":"Nature reviews. Molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/23594950","citation_count":465,"is_preprint":false},{"pmid":"27401552","id":"PMC_27401552","title":"RB1: a prototype tumor suppressor and an enigma.","date":"2016","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/27401552","citation_count":353,"is_preprint":false},{"pmid":"2856251","id":"PMC_2856251","title":"Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung.","date":"1988","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/2856251","citation_count":309,"is_preprint":false},{"pmid":"15716956","id":"PMC_15716956","title":"Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/15716956","citation_count":308,"is_preprint":false},{"pmid":"20686481","id":"PMC_20686481","title":"Rb regulates fate choice and lineage commitment in vivo.","date":"2010","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/20686481","citation_count":271,"is_preprint":false},{"pmid":"9326598","id":"PMC_9326598","title":"RB and hbrm cooperate to repress the activation functions of E2F1.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9326598","citation_count":262,"is_preprint":false},{"pmid":"9020586","id":"PMC_9020586","title":"RB kinases and RB-binding proteins: new points of view.","date":"1997","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/9020586","citation_count":226,"is_preprint":false},{"pmid":"29719458","id":"PMC_29719458","title":"Molecular signaling of ginsenosides Rb1, Rg1, and Rg3 and their mode of actions.","date":"2017","source":"Journal of ginseng research","url":"https://pubmed.ncbi.nlm.nih.gov/29719458","citation_count":190,"is_preprint":false},{"pmid":"25252974","id":"PMC_25252974","title":"Rb suppresses human cone-precursor-derived retinoblastoma tumours.","date":"2014","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/25252974","citation_count":186,"is_preprint":false},{"pmid":"22787429","id":"PMC_22787429","title":"RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation.","date":"2012","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/22787429","citation_count":169,"is_preprint":false},{"pmid":"11583618","id":"PMC_11583618","title":"Linking the Rb and polycomb pathways.","date":"2001","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/11583618","citation_count":160,"is_preprint":false},{"pmid":"20145169","id":"PMC_20145169","title":"Targeting the RB-pathway in cancer therapy.","date":"2010","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/20145169","citation_count":158,"is_preprint":false},{"pmid":"2601691","id":"PMC_2601691","title":"Mutations in the RB1 gene and their effects on transcription.","date":"1989","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/2601691","citation_count":157,"is_preprint":false},{"pmid":"23359405","id":"PMC_23359405","title":"RB1 in cancer: different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis.","date":"2013","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/23359405","citation_count":153,"is_preprint":false},{"pmid":"31174843","id":"PMC_31174843","title":"Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy.","date":"2019","source":"Trends in cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31174843","citation_count":150,"is_preprint":false},{"pmid":"21295686","id":"PMC_21295686","title":"RB1, development, and cancer.","date":"2011","source":"Current topics in developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/21295686","citation_count":145,"is_preprint":false},{"pmid":"27889452","id":"PMC_27889452","title":"An RB-EZH2 Complex Mediates Silencing of Repetitive DNA Sequences.","date":"2016","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/27889452","citation_count":141,"is_preprint":false},{"pmid":"10502774","id":"PMC_10502774","title":"RB1 gene mutations in retinoblastoma.","date":"1999","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/10502774","citation_count":137,"is_preprint":false},{"pmid":"11204276","id":"PMC_11204276","title":"Promoter hypermethylation of the RB1 gene in glioblastomas.","date":"2001","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11204276","citation_count":137,"is_preprint":false},{"pmid":"17979151","id":"PMC_17979151","title":"From G0 to S phase: a view of the roles played by the retinoblastoma (Rb) family members in the Rb-E2F pathway.","date":"2007","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17979151","citation_count":127,"is_preprint":false},{"pmid":"10339596","id":"PMC_10339596","title":"p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice.","date":"1999","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10339596","citation_count":127,"is_preprint":false},{"pmid":"20682695","id":"PMC_20682695","title":"Antiobesity and antihyperglycemic effects of ginsenoside Rb1 in rats.","date":"2010","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/20682695","citation_count":127,"is_preprint":false},{"pmid":"22318235","id":"PMC_22318235","title":"RB: mitotic implications of a tumour suppressor.","date":"2012","source":"Nature reviews. Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22318235","citation_count":124,"is_preprint":false},{"pmid":"12362273","id":"PMC_12362273","title":"RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12362273","citation_count":123,"is_preprint":false},{"pmid":"9695821","id":"PMC_9695821","title":"The caspase-RB connection in cell death.","date":"1998","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/9695821","citation_count":122,"is_preprint":false},{"pmid":"11063932","id":"PMC_11063932","title":"Chromatin remodeling and Rb activity.","date":"2000","source":"Current opinion in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/11063932","citation_count":105,"is_preprint":false},{"pmid":"11073990","id":"PMC_11073990","title":"A novel Rb- and p300-binding protein inhibits transactivation by MyoD.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11073990","citation_count":105,"is_preprint":false},{"pmid":"20807803","id":"PMC_20807803","title":"The RB-E2F1 pathway regulates autophagy.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20807803","citation_count":102,"is_preprint":false},{"pmid":"11509974","id":"PMC_11509974","title":"Neurotrophic and neuroprotective actions of ginsenosides Rb(1) and Rg(1).","date":"2001","source":"Planta medica","url":"https://pubmed.ncbi.nlm.nih.gov/11509974","citation_count":99,"is_preprint":false},{"pmid":"30111539","id":"PMC_30111539","title":"Control of the Restriction Point by Rb and p21.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/30111539","citation_count":97,"is_preprint":false},{"pmid":"24509483","id":"PMC_24509483","title":"RB1 gene inactivation by chromothripsis in human retinoblastoma.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/24509483","citation_count":93,"is_preprint":false},{"pmid":"16936739","id":"PMC_16936739","title":"RB, the conductor that orchestrates life, death and differentiation.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16936739","citation_count":86,"is_preprint":false},{"pmid":"28812991","id":"PMC_28812991","title":"The Retinoblastoma (RB) Tumor Suppressor: Pushing Back against Genome Instability on Multiple Fronts.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28812991","citation_count":84,"is_preprint":false},{"pmid":"11764090","id":"PMC_11764090","title":"Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas.","date":"2001","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/11764090","citation_count":83,"is_preprint":false},{"pmid":"18089787","id":"PMC_18089787","title":"Role of Rb-dependent and Rb-independent functions of papillomavirus E7 oncogene in head and neck cancer.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18089787","citation_count":82,"is_preprint":false},{"pmid":"22553621","id":"PMC_22553621","title":"Epidemiology and Rb1 gene of retinoblastoma.","date":"2011","source":"International journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/22553621","citation_count":79,"is_preprint":false},{"pmid":"27923835","id":"PMC_27923835","title":"RB Loss Promotes Prostate Cancer Metastasis.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27923835","citation_count":76,"is_preprint":false},{"pmid":"9467937","id":"PMC_9467937","title":"Expression of p16 induces transcriptional downregulation of the RB gene.","date":"1998","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9467937","citation_count":74,"is_preprint":false},{"pmid":"10037171","id":"PMC_10037171","title":"Alterations of Rb pathway (Rb-p16INK4-cyclin D1) in preinvasive bronchial lesions.","date":"1999","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/10037171","citation_count":74,"is_preprint":false},{"pmid":"16616919","id":"PMC_16616919","title":"The arginine methyltransferase PRMT2 binds RB and regulates E2F function.","date":"2006","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/16616919","citation_count":72,"is_preprint":false},{"pmid":"7880533","id":"PMC_7880533","title":"p53 and Rb: their cellular roles.","date":"1994","source":"Current opinion in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/7880533","citation_count":71,"is_preprint":false},{"pmid":"11420729","id":"PMC_11420729","title":"The Rb/chromatin connection and epigenetic control: opinion.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11420729","citation_count":67,"is_preprint":false},{"pmid":"15161302","id":"PMC_15161302","title":"Competitive Na(+) and Rb(+) binding in the minor groove of DNA.","date":"2004","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/15161302","citation_count":65,"is_preprint":false},{"pmid":"35058726","id":"PMC_35058726","title":"Recent progress (2015-2020) in the investigation of the pharmacological effects and mechanisms of ginsenoside Rb1, a main active ingredient in Panax ginseng Meyer.","date":"2021","source":"Journal of ginseng research","url":"https://pubmed.ncbi.nlm.nih.gov/35058726","citation_count":62,"is_preprint":false},{"pmid":"1524989","id":"PMC_1524989","title":"Studies of the RB1 gene and the p53 gene in human osteosarcomas.","date":"1992","source":"Pediatric hematology and oncology","url":"https://pubmed.ncbi.nlm.nih.gov/1524989","citation_count":56,"is_preprint":false},{"pmid":"19601762","id":"PMC_19601762","title":"The rb pathway and cancer therapeutics.","date":"2009","source":"Current drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/19601762","citation_count":55,"is_preprint":false},{"pmid":"35964818","id":"PMC_35964818","title":"Novel insights into RB1 mutation.","date":"2022","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/35964818","citation_count":54,"is_preprint":false},{"pmid":"34359636","id":"PMC_34359636","title":"Targeting RB1 Loss in Cancers.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34359636","citation_count":53,"is_preprint":false},{"pmid":"8501537","id":"PMC_8501537","title":"Retinoblastoma (Rb) gene product expression in lymphomas. Correlation with Ki67 growth fraction.","date":"1993","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/8501537","citation_count":53,"is_preprint":false},{"pmid":"1329054","id":"PMC_1329054","title":"Analysis of retinoblastoma (RB) gene deletion in human prostatic carcinomas.","date":"1992","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/1329054","citation_count":52,"is_preprint":false},{"pmid":"21059867","id":"PMC_21059867","title":"Rb/E2F regulates expression of neogenin during neuronal migration.","date":"2010","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/21059867","citation_count":50,"is_preprint":false},{"pmid":"11435948","id":"PMC_11435948","title":"The Rb pathway in neurogenesis.","date":"2001","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/11435948","citation_count":44,"is_preprint":false},{"pmid":"38926571","id":"PMC_38926571","title":"An intermediate Rb-E2F activity state safeguards proliferation commitment.","date":"2024","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/38926571","citation_count":43,"is_preprint":false},{"pmid":"34862364","id":"PMC_34862364","title":"Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34862364","citation_count":43,"is_preprint":false},{"pmid":"21249182","id":"PMC_21249182","title":"Zebrafish usp39 mutation leads to rb1 mRNA splicing defect and pituitary lineage expansion.","date":"2011","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21249182","citation_count":43,"is_preprint":false},{"pmid":"17369843","id":"PMC_17369843","title":"RB1 and TP53 pathways in radiation-induced sarcomas.","date":"2007","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17369843","citation_count":42,"is_preprint":false},{"pmid":"31238254","id":"PMC_31238254","title":"The SOX4/miR-17-92/RB1 Axis Promotes Prostate Cancer Progression.","date":"2019","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/31238254","citation_count":39,"is_preprint":false},{"pmid":"25585568","id":"PMC_25585568","title":"NUSAP1 expression is upregulated by loss of RB1 in prostate cancer cells.","date":"2015","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/25585568","citation_count":39,"is_preprint":false},{"pmid":"8764839","id":"PMC_8764839","title":"RB [corrected] as a modulator of transcription.","date":"1996","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/8764839","citation_count":39,"is_preprint":false},{"pmid":"16936741","id":"PMC_16936741","title":"Rb, whi it's not just for metazoans anymore.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16936741","citation_count":38,"is_preprint":false},{"pmid":"20100864","id":"PMC_20100864","title":"Regulation of RB transcription in vivo by RB family members.","date":"2010","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20100864","citation_count":38,"is_preprint":false},{"pmid":"21478154","id":"PMC_21478154","title":"Rb1 gene inactivation expands satellite cell and postnatal myoblast pools.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21478154","citation_count":35,"is_preprint":false},{"pmid":"18097988","id":"PMC_18097988","title":"Molecular genetics of RB1--the retinoblastoma gene.","date":"2007","source":"Seminars in ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/18097988","citation_count":35,"is_preprint":false},{"pmid":"16936754","id":"PMC_16936754","title":"Involvement of RB gene family in tumor angiogenesis.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16936754","citation_count":35,"is_preprint":false},{"pmid":"17100597","id":"PMC_17100597","title":"Rb at the interface between cell cycle and apoptotic decisions.","date":"2006","source":"Current molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17100597","citation_count":34,"is_preprint":false},{"pmid":"27645778","id":"PMC_27645778","title":"Dephosphorylation of the Retinoblastoma protein (Rb) inhibits cancer cell EMT via Zeb.","date":"2016","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/27645778","citation_count":34,"is_preprint":false},{"pmid":"12027450","id":"PMC_12027450","title":"Active RB elicits late G1/S inhibition.","date":"2002","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/12027450","citation_count":34,"is_preprint":false},{"pmid":"28300839","id":"PMC_28300839","title":"Bidirectional transcription of Linc00441 and RB1 via H3K27 modification-dependent way promotes hepatocellular carcinoma.","date":"2017","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/28300839","citation_count":34,"is_preprint":false},{"pmid":"9110405","id":"PMC_9110405","title":"Genes in the RB pathway and their knockout in mice.","date":"1996","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/9110405","citation_count":32,"is_preprint":false},{"pmid":"35023944","id":"PMC_35023944","title":"Ginsenoside Rb1 Protects Against Diabetic Cardiomyopathy by Regulating the Adipocytokine Pathway.","date":"2022","source":"Journal of inflammation research","url":"https://pubmed.ncbi.nlm.nih.gov/35023944","citation_count":32,"is_preprint":false},{"pmid":"20614030","id":"PMC_20614030","title":"RB1CC1 activates RB1 pathway and inhibits proliferation and cologenic survival in human cancer.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20614030","citation_count":31,"is_preprint":false},{"pmid":"16449662","id":"PMC_16449662","title":"An E2F binding-deficient Rb1 protein partially rescues developmental defects associated with Rb1 nullizygosity.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16449662","citation_count":31,"is_preprint":false},{"pmid":"7883788","id":"PMC_7883788","title":"The role of the p53 and Rb-1 genes in cancer, development and apoptosis.","date":"1994","source":"Journal of cell science. Supplement","url":"https://pubmed.ncbi.nlm.nih.gov/7883788","citation_count":30,"is_preprint":false},{"pmid":"20551090","id":"PMC_20551090","title":"Imprinting of RB1 (the new kid on the block).","date":"2010","source":"Briefings in functional genomics","url":"https://pubmed.ncbi.nlm.nih.gov/20551090","citation_count":29,"is_preprint":false},{"pmid":"15933756","id":"PMC_15933756","title":"Alterations of the RB1 gene in dedifferentiated liposarcoma.","date":"2005","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/15933756","citation_count":29,"is_preprint":false},{"pmid":"20551167","id":"PMC_20551167","title":"RB's original CIN?","date":"2010","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/20551167","citation_count":28,"is_preprint":false},{"pmid":"15536000","id":"PMC_15536000","title":"Developmental defects in Rb-deficient retinae.","date":"2004","source":"Vision research","url":"https://pubmed.ncbi.nlm.nih.gov/15536000","citation_count":28,"is_preprint":false},{"pmid":"19437535","id":"PMC_19437535","title":"RB1CC1 activates the promoter and expression of RB1 in human cancer.","date":"2009","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19437535","citation_count":28,"is_preprint":false},{"pmid":"9156653","id":"PMC_9156653","title":"The retinoblastoma susceptibility gene RB-1 in multiple myeloma.","date":"1997","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/9156653","citation_count":27,"is_preprint":false},{"pmid":"10928172","id":"PMC_10928172","title":"Infrequent alternations of RB pathway (Rb-p16INK4A-cyclinD1) in adenoid cystic carcinoma of salivary glands.","date":"2000","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10928172","citation_count":27,"is_preprint":false},{"pmid":"30584916","id":"PMC_30584916","title":"Comprehensive characterization of RB1 mutant and MYCN amplified retinoblastoma cell lines.","date":"2018","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/30584916","citation_count":26,"is_preprint":false},{"pmid":"24150016","id":"PMC_24150016","title":"Rb1 family mutation is sufficient for sarcoma initiation.","date":"2013","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/24150016","citation_count":25,"is_preprint":false},{"pmid":"21399612","id":"PMC_21399612","title":"RB regulates pancreas development by stabilizing Pdx1.","date":"2011","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/21399612","citation_count":25,"is_preprint":false},{"pmid":"11845284","id":"PMC_11845284","title":"Spam1 (PH-20) mutations and sperm dysfunction in mice with the Rb(6.16) or Rb(6.15) translocation.","date":"2001","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/11845284","citation_count":25,"is_preprint":false},{"pmid":"38593619","id":"PMC_38593619","title":"Ginsenoside Rb1 attenuates doxorubicin induced cardiotoxicity by suppressing autophagy and ferroptosis.","date":"2024","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/38593619","citation_count":24,"is_preprint":false},{"pmid":"22505819","id":"PMC_22505819","title":"Effects of ginsenoside Rb₁ on skin changes.","date":"2012","source":"Journal of biomedicine & biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/22505819","citation_count":24,"is_preprint":false},{"pmid":"32244804","id":"PMC_32244804","title":"Tumor Milieu Controlled by RB Tumor Suppressor.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32244804","citation_count":23,"is_preprint":false},{"pmid":"24282601","id":"PMC_24282601","title":"The origin of the RB1 imprint.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24282601","citation_count":23,"is_preprint":false},{"pmid":"34850045","id":"PMC_34850045","title":"Alterations in the RB Pathway With Inactivation of RB1 Characterize Glioblastomas With a Primitive Neuronal Component.","date":"2021","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/34850045","citation_count":23,"is_preprint":false},{"pmid":"22484813","id":"PMC_22484813","title":"Cooperation between Rb and Arf in suppressing mouse retinoblastoma.","date":"2012","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/22484813","citation_count":23,"is_preprint":false},{"pmid":"37087793","id":"PMC_37087793","title":"Ginsenoside Rb1 for overcoming cisplatin-insensitivity of A549/DDP cells in vitro and vivo through the dual-inhibition on two efflux pumps of ABCB1 and PTCH1.","date":"2023","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37087793","citation_count":22,"is_preprint":false},{"pmid":"9545437","id":"PMC_9545437","title":"RB and apoptotic cell death.","date":"1998","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/9545437","citation_count":21,"is_preprint":false},{"pmid":"29733964","id":"PMC_29733964","title":"Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation.","date":"2018","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/29733964","citation_count":21,"is_preprint":false},{"pmid":"27270425","id":"PMC_27270425","title":"SENP1-modulated sumoylation regulates retinoblastoma protein (RB) and Lamin A/C interaction and stabilization.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27270425","citation_count":21,"is_preprint":false},{"pmid":"9517499","id":"PMC_9517499","title":"Expression of the retinoblastoma tumor suppressor gene (RB-1) in acute leukemia.","date":"1998","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/9517499","citation_count":20,"is_preprint":false},{"pmid":"26677227","id":"PMC_26677227","title":"Ras Regulates Rb via NORE1A.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26677227","citation_count":20,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":42121,"output_tokens":6464,"usd":0.111661,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15361,"output_tokens":5397,"usd":0.105865,"stage2_stop_reason":"end_turn"},"total_usd":0.217526,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"RB associates with the histone methyltransferase SUV39H1 and the methyl-lysine binding protein HP1 via its pocket domain in vivo. RB directs methylation of histone H3 (Lys9) and recruits HP1 to the cyclin E promoter, repressing cyclin E and cyclin A2 gene expression through chromatin-level silencing.\",\n      \"method\": \"Co-immunoprecipitation, chromatin immunoprecipitation (ChIP), transient transfection reporter assays, SUV39H1-disrupted fibroblasts\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, ChIP with endogenous proteins, functional genetic (knockout fibroblasts), and reporter assays; multiple orthogonal methods in one rigorous study\",\n      \"pmids\": [\"11484059\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"RB physically interacts with hBRM (a SWI/SNF ATPase subunit) and can simultaneously bind both E2F1 and hBRM, targeting hBRM to E2F1. RB and hBRM cooperate to repress E2F1 transcriptional activity, and this cooperation requires the RB-binding domain and NTP-binding site of hBRM but not its bromodomain.\",\n      \"method\": \"Co-immunoprecipitation in vivo, transient transfection reporter assays, domain-deletion and mutation analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, functional reporter assays, structure-function mutagenesis of hBRM, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"9326598\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SMYD2 methylates RB1 protein at lysine 810 in vitro and in vivo. This lysine 810 methylation enhances subsequent phosphorylation of RB1 at Ser807/811, accelerates E2F transcriptional activity, and promotes cell cycle progression through G1/S.\",\n      \"method\": \"In vitro methyltransferase assay, LC-MS/MS identification of methylation site, immunoprecipitation, cell cycle analysis, SMYD2 knockdown\",\n      \"journal\": \"Neoplasia (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic assay with mass spectrometry site identification, validated in vivo by Co-IP and cell cycle readout; multiple orthogonal methods in single study\",\n      \"pmids\": [\"22787429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"RB colocalizes with Polycomb group (PcG) protein complexes in the nucleus and forms a repressor complex with PcG proteins that blocks entry into mitosis. RB is required for the association of PcG complexes with their nuclear targets.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence colocalization, cell cycle analysis\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP and localization with functional cell cycle readout, but single lab and limited mechanistic depth in the abstract\",\n      \"pmids\": [\"11583618\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"pRB uses a cell-cycle-independent interaction with E2F1 to recruit EZH2 to diverse repetitive genomic sequences (simple repeats, satellites, LINEs, endogenous retroviruses). An F832A point mutation in Rb1 abolishes this recruitment; loss of pRB-EZH2 complexes disperses H3K27me3 from these repeat loci and permits their expression.\",\n      \"method\": \"Co-immunoprecipitation, ChIP-seq, knock-in mouse model (F832A mutation), gene expression analysis\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — structure-function mutation in vivo, ChIP-seq, reciprocal Co-IP, mutant mouse strain with defined phenotype; multiple orthogonal methods\",\n      \"pmids\": [\"27889452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CDK2- or CDK4/6-mediated phosphorylation of RB1 at the conserved T373 residue creates a primed, intermediate state of partial E2F activation. T373-phosphorylated RB remains bound to chromatin but dissociates fully only upon hyperphosphorylation at many sites. T373 is preferentially phosphorylated initially due to its slower dephosphorylation rate. This intermediate state allows cells to remain reversibly uncommitted before triggering the positive CDK2-E2F feedback loop.\",\n      \"method\": \"Single-cell live imaging of E2F and CDK2 reporters, phospho-specific immunofluorescence, pharmacological CDK inhibition, site-specific RB phosphorylation analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — single-cell live reporters, phospho-site-specific biochemistry, multiple pharmacological perturbations; rigorous mechanistic dissection with multiple orthogonal approaches\",\n      \"pmids\": [\"38926571\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The arginine methyltransferase PRMT2 binds RB through its AdoMet binding domain (unlike PRMT1, PRMT3, PRMT4 which do not bind RB). PRMT2 represses E2F1 transcriptional activity in an RB-dependent manner by forming a ternary complex with E2F1 in the presence of RB. PRMT2-null MEFs show increased E2F activity and accelerated S-phase entry.\",\n      \"method\": \"Co-immunoprecipitation, reporter assays, PRMT2 gene targeting in mice, cell cycle analysis\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, reporter assays, PRMT2 knockout mice with defined cellular phenotype; multiple orthogonal methods and genetic validation\",\n      \"pmids\": [\"16616919\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RB physically associates with and stabilizes the pancreatic transcription factor Pdx-1 via a conserved RB-interaction motif (RIM) in Pdx-1 that is also present in E2Fs. Point mutations within the RIM reduce RB-Pdx-1 complex formation, destabilize Pdx-1, and promote its proteasomal degradation. Glucose regulates RB/Pdx-1 complex formation and Pdx-1 stability. RB occupies promoters of β-cell-specific genes; RB knockdown reduces Pdx-1 and its target gene expression.\",\n      \"method\": \"Co-immunoprecipitation, site-directed mutagenesis (RIM mutations), ChIP, siRNA knockdown, proteasome inhibitor experiments, RB-deficient mouse phenotype\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, structure-function mutagenesis, ChIP, in vivo mouse model; multiple orthogonal methods establishing a novel RB substrate interaction mechanism\",\n      \"pmids\": [\"21399612\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Dephosphorylated RB associates with ZEB1 (a transcriptional regulator of EMT markers E- and N-cadherin) and inhibits ZEB1 transcriptional activity. PP1-mediated dephosphorylation of RB (via PNUTS knockdown) reduces EMT in invasive cancer cells in 3D culture in an RB-dependent manner.\",\n      \"method\": \"shRNA silencing of PNUTS, Co-immunoprecipitation, 3D Matrigel culture, reporter assays, Western blot\",\n      \"journal\": \"Cancer biology & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP, functional cellular assay, and RB-null controls confirm RB dependence; single lab, single paper\",\n      \"pmids\": [\"27645778\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SUMO1 conjugation of RB and Lamin A/C, modulated by the SUMO protease SENP1, is required for the RB-Lamin A/C interaction. This SUMO1-dependent complex protects both RB and Lamin A/C from proteasomal degradation.\",\n      \"method\": \"Sumoylation assays, Co-immunoprecipitation, SENP1 overexpression/knockdown, proteasome inhibitor experiments\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP, biochemical sumoylation assay, functional proteasomal degradation readout; single lab, single paper\",\n      \"pmids\": [\"27270425\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RB triggers autophagy through repression of E2F1 activity. RB activators p16INK4a and p27/Kip1 induce autophagy in an RB-dependent manner. E2F1 antagonizes RB-induced autophagy, and downregulation of E2F1 leads to high autophagy levels.\",\n      \"method\": \"Autophagy assays, RB/E2F1 overexpression and knockdown, epistasis by double knockdown\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — genetic epistasis (RB-dependent rescue), functional autophagy readout; single lab, single paper\",\n      \"pmids\": [\"20807803\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Ras induces formation of a complex between NORE1A and the phosphatase PP1A, which promotes dephosphorylation and activation of RB. Suppression of RB reduces NORE1A-induced senescence, placing RB downstream of Ras/NORE1A/PP1A in oncogene-induced senescence.\",\n      \"method\": \"Co-immunoprecipitation, RB knockdown, senescence assays, PP1A-NORE1A interaction pulldown\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP, epistasis via RB suppression, functional senescence readout; single lab, single paper\",\n      \"pmids\": [\"26677227\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Aspartate beta-hydroxylase (ASPH) promotes direct protein interaction between RB1, cyclin-dependent kinases, and cyclins, thereby promoting RB1 phosphorylation. ASPH knockdown reduces RB1 phosphorylation and inhibits cholangiocarcinoma growth in vitro and in vivo.\",\n      \"method\": \"Co-immunoprecipitation, ASPH knockdown, phospho-RB1 immunoassay, xenograft mouse model, 2-OG dioxygenase inhibitor treatment\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP demonstrating RB1-CDK-cyclin complex modulated by ASPH, supported by in vivo xenograft; single lab, single paper\",\n      \"pmids\": [\"29733964\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Active (constitutively hypophosphorylated) RB inhibits cell cycle progression at the late G1/S boundary not by suppressing cyclin E expression or CDK2/cyclin E activity, but by causing coordinate transcriptional repression and accelerated degradation of cyclin A, attenuating CDK2/cyclin A-dependent events.\",\n      \"method\": \"Inducible constitutively active RB allele (PSM-RB), cell cycle synchronization, mRNA and protein analysis, CDK kinase assays, centrosome duplication assay\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — inducible gain-of-function allele, kinase assays, multiple mechanistic readouts; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"12027450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Rb1 protein (pRb) binds to Runx2 and potentiates its osteogenic differentiation activity. pRb acts with E2F to suppress PPARγ (master adipogenic activator). Rb status thus controls mesenchymal stem cell fate choice between osteoblast and adipocyte lineages in vivo.\",\n      \"method\": \"Mouse conditional knockout models, lineage tracing, in vivo bone and adipose tissue phenotyping, co-immunoprecipitation (referenced in abstract as prior in vitro work; in vivo epistasis confirmed here)\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo conditional knockout mouse models with defined lineage phenotypes; some mechanistic claims (Runx2 binding) based on referenced prior in vitro work, confirmed in vivo by genetic epistasis\",\n      \"pmids\": [\"20686481\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"RB1 is cleaved by caspase-3-like activity at its carboxyl terminus during apoptosis. During apoptosis, hyperphosphorylated RB is first dephosphorylated to the hypophosphorylated form, which is then cleaved by caspase activity. The unphosphorylated (p110) form of RB is resistant to cleavage and functions as an inhibitor of apoptosis; a caspase-resistant RB1 attenuates the death response to TNF-α.\",\n      \"method\": \"In vitro caspase cleavage assays, cell death assays with TNF-α, immunoblotting of RB phospho-forms, caspase-resistant mutant expression\",\n      \"journal\": \"Trends in cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical caspase assays, functional caspase-resistant mutant; replicated across multiple studies cited in abstract\",\n      \"pmids\": [\"9695821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"RB1CC1 (FIP200) directly binds to a GC-rich region 201 bp upstream of the RB1 promoter and activates RB1 transcription. The C-terminus of RB1CC1 is required for its nuclear localization and subsequent RB1 promoter activation.\",\n      \"method\": \"Chromatin immunoprecipitation, luciferase reporter assays, electrophoretic mobility shift assay (EMSA), Western blot, immunohistochemistry\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, EMSA, and reporter assays establishing direct promoter binding; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"19437535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RB1CC1 (FIP200) forms a nuclear complex with hSNF5 and/or p53 that activates transcription of RB1, p16, and p21. RB1CC1 binds hSNF5 and p53 as identified by immunoprecipitation and immunofluorescence.\",\n      \"method\": \"Co-immunoprecipitation, chromatin immunoprecipitation, luciferase reporter assays, flow cytometry, immunofluorescence\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP identifying complex partners, ChIP, and reporter assays; single lab, single paper\",\n      \"pmids\": [\"20614030\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The RB/E2F pathway directly regulates neogenin expression: RB represses E2F-mediated transcription of neogenin (a receptor for netrin-1 involved in cell migration), and E2F3 occupies E2F consensus sites on the neogenin promoter in native chromatin. Loss of Rb results in increased neogenin expression, aberrant neuronal migration and adhesion in response to netrin-1.\",\n      \"method\": \"ChIP, promoter reporter assays, Rb conditional knockout mouse, ex vivo electroporation, migration assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP with E2F3 antibody on native chromatin, reporter assays, conditional KO mouse with functional neuronal migration phenotype; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"21059867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Loss of Rb1 in satellite cells (using conditional Pax7CreER;Rb1 deletion) causes re-entry of quiescent satellite cells into replication, resulting in 5-fold expansion of satellite cells and 3-fold increase in myoblasts, while diminishing terminal differentiation. This establishes pRb as a regulator of muscle satellite cell quiescence.\",\n      \"method\": \"Conditional mouse knockout (Pax7CreER;Rb1flox), satellite cell counting, BrdU incorporation, cardiotoxin injury/regeneration assay, pharmacological PP1 inhibition\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean conditional KO with specific cellular phenotypes; single lab, in vivo mouse model with multiple readouts\",\n      \"pmids\": [\"21478154\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Mitf cooperates physically with Rb1 to potentiate Mitf-mediated transcriptional activation. The interaction between Mitf and hypophosphorylated Rb1 enhances Mitf's ability to activate the p21Cip1 promoter, leading to G1 arrest. Mitf-induced cell cycle arrest depends on this p21Cip1 induction.\",\n      \"method\": \"Co-immunoprecipitation, luciferase reporter assays, cell cycle analysis, p21Cip1 promoter activation assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, promoter reporter with functional rescue, cell cycle readout; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"15716956\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"RB family members (p107 and p130) and E2F transcription factors bind directly to the RB1 promoter in vivo, modulating RB transcription as a regulatory feedback mechanism in specific cell populations.\",\n      \"method\": \"ChIP on RB1 promoter, transgenic eGFP-BAC reporter mice, genetic analyses with Rb, p107, and p130 mutant alleles\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP establishing direct promoter binding, validated in vivo with reporter transgenic and triple-mutant mice; single lab\",\n      \"pmids\": [\"20100864\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"RB loss induces upregulation of the cell motility receptor RHAMM via the RB/E2F pathway, which stabilizes F-actin polymerization by controlling ROCK signaling, promoting epithelial-mesenchymal transition, motility, and invasion. Pharmacological or genetic inhibition of RHAMM blocks the metastatic phenotype caused by RB loss.\",\n      \"method\": \"Multiple murine cancer models with RB knockout, gene expression analysis, pharmacological RHAMM inhibition, RHAMM genetic modulation, invasion/motility assays, F-actin polymerization assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple in vivo mouse models, defined pathway (RB/E2F→RHAMM→ROCK→F-actin), pharmacological and genetic rescue; single lab\",\n      \"pmids\": [\"27923835\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"An E2F-binding-deficient Rb1 point mutant (R654W, defective for binding E2F1, E2F2, E2F3) rescues erythrocyte and fetal liver macrophage differentiation defects in Rb1-null embryos, extending survival by at least 2 days beyond null lethality, but does not rescue retinal differentiation defects. This establishes that Rb1's role in certain differentiation events is genetically separable from E2F1/2/3 binding.\",\n      \"method\": \"Knock-in mouse model (R654W mutation), embryonic phenotype analysis, histology, cell cycle analysis, comparison with null embryos\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vivo knock-in mutagenesis with precise separation-of-function, multiple tissue phenotypes analyzed; rigorous genetic approach establishing mechanistic separation\",\n      \"pmids\": [\"16449662\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Rb and p27 cooperate to suppress tumor development through overlapping but distinct pathways: Rb+/-p27-/- double mutant mice develop more aggressive and earlier-onset pituitary and thyroid tumors than either single mutant, and pituitary tumor development in Rb+/- mice correlates with reduced p27 expression. This genetic epistasis places p27 and Rb on overlapping but not strictly linear tumor suppressor pathways.\",\n      \"method\": \"Mouse double-mutant genetic analysis (Rb+/- x p27-/-), tumor phenotype comparison, p27 mRNA and protein expression analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in vivo with defined tumor phenotypes and molecular marker analysis; single study, in vivo mouse models\",\n      \"pmids\": [\"10339596\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"RB1 (pRB) is a multifunctional tumor suppressor that primarily restrains cell cycle progression by binding E2F transcription factors through its pocket domain and actively repressing E2F target gene promoters via recruitment of chromatin-modifying co-repressors including HDACs, the SWI/SNF ATPase hBRM, the histone H3K9 methyltransferase SUV39H1 (which directs HP1 binding), and the H3K27 methyltransferase EZH2 (recruited in a cell-cycle-independent manner to silence repetitive sequences); pRB phosphorylation status—governed by cyclin-CDK complexes and reversed by PP1/NORE1A and related phosphatases—dictates its activity, with sequential phosphorylation first at T373 creating a primed intermediate state before full hyperphosphorylation releases E2F and triggers S-phase commitment; beyond E2F control, pRB stabilizes lineage-specific transcription factors (e.g., Pdx-1, Runx2), cooperates with Mitf to induce p21Cip1-dependent differentiation arrest, is methylated at K810 by SMYD2 to enhance CDK-mediated phosphorylation, is sumoylated in a SENP1-regulated manner enabling its protective interaction with Lamin A/C, and is cleaved by caspase-3 during apoptosis—collectively establishing pRB as an integrator of proliferation, differentiation, genome stability, and cell death signals.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"RB1 (pRB) is a tumor suppressor that restrains cell cycle progression by binding E2F transcription factors and converting their target promoters into transcriptionally silent chromatin [#0, #1]. pRB does not act simply as a steric blockade: it recruits the H3K9 methyltransferase SUV39H1 and the methyl-lysine reader HP1 to genes such as cyclin E and cyclin A2, directing histone H3 Lys9 methylation and chromatin-level repression [#0], and it physically engages the SWI/SNF ATPase hBRM to repress E2F1 activity through its RB-binding and NTP-binding modules [#1]. Through a cell-cycle-independent interaction with E2F1, pRB also delivers EZH2 to repetitive genomic sequences (satellites, LINEs, endogenous retroviruses), maintaining H3K27me3 and silencing these loci—an activity abolished by the F832A pocket mutation [#4]. pRB activity is set by its phosphorylation state: sequential CDK2/CDK4-6 phosphorylation begins at T373 to create a chromatin-bound, reversibly uncommitted intermediate before hyperphosphorylation fully releases E2F and commits cells to S phase [#5], while active hypophosphorylated pRB enforces the late G1/S boundary largely by repressing and destabilizing cyclin A [#13]. These phosphorylation events are tuned by additional modifications—SMYD2 methylation at K810 primes pRB for CDK phosphorylation [#2]—and reversed by PP1-based phosphatase activities, including a NORE1A/PP1A complex that activates pRB during Ras-induced senescence [#11]. Beyond E2F control, pRB acts as a stabilizing cofactor for lineage transcription factors, binding and protecting Pdx-1 in pancreatic β-cells [#7], potentiating Runx2-driven osteogenesis while suppressing adipogenesis to govern mesenchymal fate [#14], and cooperating with Mitf to induce p21Cip1-dependent G1 arrest [#20]; a separation-of-function knock-in (R654W) demonstrates that some differentiation roles are genetically independent of E2F1/2/3 binding [#23]. pRB additionally functions in autophagy [#10], satellite-cell quiescence [#19], suppression of EMT and metastasis through ZEB1 and the RHAMM/ROCK axis [#8, #22], and apoptosis, where caspase-3 cleaves its C-terminus and the uncleavable form acts as a death inhibitor [#15]. RB1 transcription is itself feedback-regulated by E2F and RB-family proteins binding its promoter [#21] and activated by an RB1CC1/FIP200-containing nuclear complex [#16, #17].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established that pRB represses E2F not merely by binding it but by physically recruiting a chromatin-remodeling ATPase, introducing the concept of pRB as a co-repressor scaffold.\",\n      \"evidence\": \"Co-IP and structure-function mutagenesis showing pRB simultaneously binds E2F1 and hBRM and cooperatively represses E2F1 transcription\",\n      \"pmids\": [\"9326598\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve whether hBRM acts on nucleosome positioning at endogenous E2F promoters\", \"No genome-wide map of pRB-hBRM co-occupancy\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Defined pRB as a node in apoptotic signaling by showing caspase cleavage inactivates it, linking its degradation to death-signal execution.\",\n      \"evidence\": \"In vitro caspase cleavage assays, RB phospho-form immunoblotting, and a caspase-resistant mutant in TNF-α death assays\",\n      \"pmids\": [\"9695821\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological caspase responsible in vivo not fully defined\", \"Downstream consequences of the cleaved fragment unresolved\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Placed pRB and p27 on overlapping but non-linear tumor-suppressor pathways, showing combinatorial control of endocrine tumorigenesis.\",\n      \"evidence\": \"Rb+/- x p27-/- double-mutant mouse genetics with tumor phenotype and p27 expression analysis\",\n      \"pmids\": [\"10339596\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of cooperativity not delineated\", \"Tissue specificity of the genetic interaction unexplained\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Revealed the chromatin-silencing mechanism of pRB repression—recruitment of SUV39H1/HP1 to deposit H3K9 methylation at cell-cycle promoters—and its link to Polycomb-mediated mitotic control.\",\n      \"evidence\": \"Reciprocal Co-IP, ChIP on the cyclin E promoter in SUV39H1-knockout fibroblasts; separate Co-IP/colocalization with PcG complexes and cell-cycle readouts\",\n      \"pmids\": [\"11484059\", \"11583618\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of HP1/SUV39H1 recruitment across the E2F target set not established\", \"PcG-pRB complex composition only partially defined (Medium-confidence)\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Clarified how active pRB enforces the late G1/S boundary, showing the block operates through cyclin A repression and degradation rather than cyclin E/CDK2 suppression.\",\n      \"evidence\": \"Inducible constitutively active PSM-RB allele with CDK kinase assays, mRNA/protein and centrosome duplication readouts\",\n      \"pmids\": [\"12027450\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of accelerated cyclin A degradation not identified\", \"Single inducible system\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Expanded pRB's repressive repertoire and differentiation roles—identifying PRMT2 as an RB-dependent E2F1 co-repressor, Runx2/PPARγ control of mesenchymal fate, and an E2F-independent differentiation function via the R654W separation-of-function allele.\",\n      \"evidence\": \"PRMT2-null MEFs and ternary-complex Co-IP; conditional Rb knockout lineage tracing; R654W knock-in mouse rescue of erythroid/macrophage but not retinal defects\",\n      \"pmids\": [\"16616919\", \"20686481\", \"16449662\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the E2F-independent effectors in differentiation tissues unknown\", \"Whether PRMT2 methylation activity is required for repression not resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showed RB1 expression is transcriptionally controlled by FIP200/RB1CC1 binding its promoter, identifying an upstream regulator of pRB abundance.\",\n      \"evidence\": \"ChIP, EMSA, and luciferase reporter assays mapping RB1CC1 binding to a GC-rich element upstream of RB1\",\n      \"pmids\": [\"19437535\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological signals controlling RB1CC1 nuclear activity unclear\", \"Single-lab promoter study\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Extended pRB function into autophagy, neuronal migration, and protein-stabilizing cofactor roles, and defined an RB1CC1/hSNF5/p53 transcriptional activation complex for RB1, p16 and p21.\",\n      \"evidence\": \"RB/E2F1 epistasis autophagy assays; ChIP/reporter and conditional KO for neogenin; Co-IP/RIM mutagenesis stabilizing Pdx-1; Co-IP/ChIP for the RB1CC1-hSNF5-p53 complex\",\n      \"pmids\": [\"20807803\", \"21059867\", \"21399612\", \"20614030\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Autophagy effector genes downstream of E2F1 unidentified\", \"Whether the RB1CC1-p53 complex operates in normal vs stressed cells unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined pRB as a guardian of stem-cell quiescence, showing its loss drives quiescent satellite cells back into cycle while impairing differentiation.\",\n      \"evidence\": \"Pax7CreER;Rb1flox conditional knockout with cell counting, BrdU, injury/regeneration, and PP1 inhibition\",\n      \"pmids\": [\"21478154\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Phosphatase regulating pRB in satellite cells not definitively identified\", \"Single in vivo system\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified a post-translational priming mechanism—SMYD2 methylation of pRB at K810 enhancing CDK phosphorylation—linking lysine methylation to cell-cycle release.\",\n      \"evidence\": \"In vitro methyltransferase assay with LC-MS/MS site mapping, Co-IP, and SMYD2-knockdown cell-cycle analysis\",\n      \"pmids\": [\"22787429\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reader of K810 methylation not identified\", \"Whether methylation directly alters CDK docking unresolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Connected pRB activation to oncogene-induced senescence through a Ras/NORE1A/PP1A dephosphorylation circuit.\",\n      \"evidence\": \"Co-IP of NORE1A-PP1A, RB suppression epistasis, and senescence assays\",\n      \"pmids\": [\"26677227\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct PP1A dephosphorylation sites on pRB not mapped\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined a cell-cycle-independent pRB-EZH2 repeat-silencing activity and additional non-cell-cycle modifications and effectors (sumoylation/Lamin A/C protection, ZEB1/RHAMM-mediated suppression of EMT and metastasis).\",\n      \"evidence\": \"F832A knock-in mouse with ChIP-seq for EZH2/H3K27me3; SUMO/SENP1 assays for Lamin A/C; PNUTS knockdown 3D culture for ZEB1; multiple RB-knockout cancer models for RHAMM/ROCK\",\n      \"pmids\": [\"27889452\", \"27270425\", \"27645778\", \"27923835\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a single pocket residue (F832) discriminates repeat from gene targets unclear\", \"Sumoylation and ZEB1 findings are Medium-confidence single-lab studies\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified ASPH as a scaffolding factor promoting RB1-CDK-cyclin complex assembly and pRB phosphorylation in cancer.\",\n      \"evidence\": \"Co-IP, ASPH knockdown with phospho-RB1 readout, xenograft model, and dioxygenase inhibition\",\n      \"pmids\": [\"29733964\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ASPH hydroxylase activity is required for complex assembly not resolved\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Resolved how pRB inactivation is graded over the cell cycle, showing T373 phosphorylation creates a chromatin-bound, reversibly uncommitted intermediate that precedes full hyperphosphorylation and S-phase commitment.\",\n      \"evidence\": \"Single-cell live imaging of E2F/CDK2 reporters, phospho-site-specific immunofluorescence, and pharmacological CDK inhibition\",\n      \"pmids\": [\"38926571\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of partial vs full E2F release not defined\", \"Phosphatase setting the slow T373 dephosphorylation rate not identified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the many pRB modifications (phosphorylation, K810 methylation, sumoylation, caspase cleavage) and its diverse partner set are integrated to select among proliferation, differentiation, senescence, autophagy, and apoptosis outcomes in a given cell remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking modification state to effector-complex choice\", \"Tissue-specific partner usage incompletely mapped\", \"Structural basis for pocket-domain discrimination among E2F, lineage factors, and co-repressors undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 4, 13, 20]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 4, 6, 7, 20]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [1, 4, 6]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 7]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 3, 4]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [0, 4]},\n      {\"term_id\": \"GO:0005635\", \"supporting_discovery_ids\": [9]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [0, 5, 13]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 4, 7, 20]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [0, 4]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [7, 14, 23]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [10]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [15]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [11]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [22, 24]}\n    ],\n    \"complexes\": [\n      \"pRB-E2F1-EZH2 repeat-silencing complex\",\n      \"pRB-SUV39H1-HP1 repressor complex\",\n      \"pRB-E2F1-hBRM (SWI/SNF) repressor complex\",\n      \"pRB-PcG repressor complex\"\n    ],\n    \"partners\": [\n      \"E2F1\",\n      \"SUV39H1\",\n      \"HP1\",\n      \"hBRM\",\n      \"EZH2\",\n      \"PRMT2\",\n      \"Pdx-1\",\n      \"Mitf\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}